Lambertson brings executive experience to the newly created position,  reinforcing Celsion’s commitment to its strategic communications and investor relations objectives LAWRENCEVILLE, N.J. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development

OVATION II Study Will Evaluate Initial and Maintenance Dosing of GEN-1 on Progression-Free Survival in a Two-Arm, Randomized Trial of Up to 130 Patients LAWRENCEVILLE, N.J. , Sept. 06, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced

  550 Patient Study Designed to Determine if ThermoDox® Can Significantly Prolong the Lives of Patients with Liver Cancer OPTIMA Study’s Hypothesis Independently Confirmed by the National Institutes of Health LAWRENCEVILLE, NJ , Sept. 05, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ:

  Funding Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program LAWRENCEVILLE, N.J. , Sept. 04, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced it has received approval from the New Jersey Economic

  Strong Balance Sheet With Cash Sufficient to Fund Operations Into the First Half of 2020 Quarterly and Year-to-Date Cash Expenses Consistent With Prior Guidance                Company to Hold Conference Call on Tuesday, August 14, 2018 at 11:00 a.m. EDT LAWRENCEVILLE, N.J. , Aug.

LAWRENCEVILLE, N.J , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended June 30, 2018 and provide an update on its development programs for ThermoDox®, its proprietary

   – The TARDOX Study, in Collaboration with University of Oxford , Evaluates the Use of Focused Ultrasound in Combination with ThermoDox® to Treat Primary and Metastatic Liver Cancer – – Imaging Studies in Patients Treated with ThermoDox® and Focused Ultrasound Demonstrated Clinical Response After

$10 Million Improvement to the Balance Sheet Provides Additional Seven Months of Operating Runway LAWRENCEVILLE, N.J. , June 28, 2018 (GLOBE NEWSWIRE) --   Celsion Corporation (NASDAQ: CLSN) (“Celsion” or “the Company”), an oncology drug development company, today announced that on June 27, 2018 it

LAWRENCEVILLE, N.J. , June 25, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that it will be added to the Russell Microcap® Index as part of the Russell indexes annual reconstitution, effective after the U.S. market opens today.

Significant Progress in Phase III Liver Cancer and Phase I/II Ovarian Cancer Studies  Supported with Solid Fundamentals and a Strong Balance Sheet                Company to Hold Conference Call on Friday, May 11, 2018 at 11:00 a.m. EDT LAWRENCEVILLE, N.J.